2Q 2025 Financial Results Nasdaq: NEO 1 July 29, 2025 Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securiti ...

Financial Performance - Revenue increased by 8% to $168 million in 1Q 2025[31, 35] - Clinical NGS revenue grew by 18%[17, 19] - Adjusted Gross Profit increased by 11% to $79 million[31] - Adjusted EBITDA improved by 102% to $7 million[15, 31] - Adjusted Gross Margin increased to 47%, a 146 bps improvement[17, 32] Operational Highlights - Clinical volume increased by 8% year-over-year, reaching 326,000 units[12, 31] - The company announced the acquisition of Pathline to strengthen its commercial presence in the Northeast[17, 25] - Clinical revenue per test improved by 3% due to mix and pricing[13, 35] Strategic Initiatives - The company submitted PanTracer LBx to MolDx[17, 42] - The company is expanding its salesforce up to 140 representatives[23] Financial Guidance - The company revised its full-year 2025 revenue guidance to $747-$759 million, representing a 13-15% year-over-year growth[38] - The company reiterated its full-year adjusted EBITDA guidance of $55-$58 million, representing a 38-45% year-over-year growth[38]